Primary Hyperaldosteronism: From A to Z

SPONSORED BY: DiaSorin, DiaSorin
Speakers
  • Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology
    Biography
      Dr. Williams is an Assistant Professor of Medicine at Harvard Medical School and Associate Physician at Brigham and Women's Hospital, Division of Endocrinology, Diabetes, and Hypertension.  He has dedicated his research efforts to unravelling the intricate relationship between genetics and environment with respect to individual susceptibility to cardiometabolic disease.  He has over 40 original publications describing the physiologic and pathologic interplay of renin-angiotensin-aldosterone system activity and dietary salt intake in hypertension, insulin resistance, heart disease, and obesity.  His work is funded through National Institutes of Health, industry, and private foundation support.
       
      Dr. Williams is an active program developer, course director, and mentor for the Harvard Medical School's Scholars in Clinical Research Program, which is a Master's degree granting program designed to train the upcoming generation of patient-oriented physician scientists.  He is also an Associate Editor of the journal Metabolism, and serves on the Board of Directors for the Association for Patient-oriented Research and for the Association for Clinical and Translational Science.

    Abstract:

    The prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%.  It is considered a secondary form of hypertension caused by inappropriate secretion of aldosterone and activation of the mineralocorticoid receptor.  As such, it is a highly treatable and potentially curable form of hypertension.  This webinar will review the prevalence, pathophysiology, screening and diagnostic studies, and treatment options for patients with primary hyperaldosteronism so that the Practitioner can accurately screen and identify cases.

    Learning objectives:

    1.  Understand the prevalence, pathophysiology and diagnostic studies for patients with primary hyperaldosteronism.
     
    2.  Be able to identify screening and treatment options for patients with primary hyperaldoseronism.
     
     


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...